Bravecto 500 mg Chewable Tablets for Medium-sized Dogs (>10 – 20 kg)

দেশ: যুক্তরাজ্য

ভাষা: ইংরেজি

সূত্র: VMD (Veterinary Medicines Directorate)

সক্রিয় উপাদান:

Fluralaner

থেকে পাওয়া:

MSD Animal Health UK Limited

এটিসি কোড:

QP53BE02

INN (আন্তর্জাতিক নাম):

Fluralaner

ফার্মাসিউটিকাল ফর্ম:

Chewable tablet

প্রেসক্রিপশন টাইপ:

POM-V - Prescription Only Medicine – Veterinarian

থেরাপিউটিক গ্রুপ:

Dogs

থেরাপিউটিক এলাকা:

Ectoparasiticide

অনুমোদন অবস্থা:

Authorized

অনুমোদন তারিখ:

2014-02-11

পণ্য বৈশিষ্ট্য

Amended Pages: April 2024
AN: 02555/2022
Page 1 of 7
SUMMARY OF THE PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bravecto 500 mg chewable tablets for medium-sized dogs (>10 – 20 kg)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Each chewable tablet contains:
BRAVECTO CHEWABLE TABLETS
FLURALANER (MG)
for medium-sized dogs (>10 – 20 kg)
500
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
Light to dark brown tablet with a smooth or slightly rough surface and
circular shape.
Some marbling, speckles or both may be visible.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of tick and flea infestations in dogs.
This veterinary medicinal product is a systemic insecticide and
acaricide that
provides:
-
immediate and persistent flea (_Ctenocephalides felis_) killing
activity for 12
weeks,
-
immediate and persistent tick killing activity for 12 weeks for_
Ixodes ricinus, _
_Dermacentor reticulatus_ and_ D. variabilis,_
-
immediate and persistent tick killing activity for 8 weeks for
_Rhipicephalus _
_sanguineus,_
-
persistent tick killing activity from 7 days to 12 weeks after
treatment for _Ixodes _
_hexagonus._
Fleas and ticks must attach to the host and commence feeding in order
to be
exposed to the active substance.
Amended Pages: April 2024
AN: 02555/2022
Page 2 of 7
The veterinary medicinal product can be used as part of a treatment
strategy for the
control of flea allergy dermatitis (FAD).
For the treatment of demodicosis caused by _Demodex_ _canis_.
For the treatment of sarcoptic mange (_Sarcoptes scabiei _var._
canis_) infestation.
For reduction of the risk of infection with _Babesia canis canis_ via
transmission by
_Dermacentor reticulatus_ for up to 12 weeks. The effect is indirect
due to the
veterinary medicinal product’s activity against the vector.
For reduction of the risk of infection with _Dipylidium caninum_ via
transmission by
_Ctenocephalides feli